These findings support future studies on IL-33 as a potential predictive biomarker for 5-FU chemosensitivity and favorable prognosis, as well as a promising adjuvant to generate effective T-mediated protective immunity against cancer, thereby improving the therapeutic efficacy of 5-FU-based regimens in the treatment of CRC. Here, IL33 is linked to colorectal carcinoma.